Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize its Novel Gastrointestinal Drug in India

Ahmedabad, India 05th June : Torrent Pharmaceuticals Limited (Torrent) today announced  that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialize  Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for  the treatment of acid related disorders – Gastroesophageal Reflux Disease (GERD). Torrent will  market Vonoprazan under its own trademark, Kabvie.  

As per a 2019 study published by Indian Journal of Gastroenterology prevalence of GERD in  Indian population is around 8.2%, with a higher prevalence of around 11.1% in urban population.  According to AWACS MAT April 2024 data, the Indian market for treatments used in GERD is  valued at INR 8,064 crore, growing at 8% CAGR over the last 4 years. Currently treatments such  as Pantoprazole (Proton Pump Inhibitors) are used to treat GERD. Availability of P-CABs such as  Kabvie will make accessible new and effective treatments of GERD for the Indian population. 

Commenting on the agreement, Aman Mehta – Director, Torrent said, “We are delighted to  commercialize this novel treatment for Indian patients. I am confident that the launch of Kabvie  will aid in reducing the disease burden of GERD and further strengthen our Gastrointestinal  offerings, augmenting our position as a leading player within the Indian Pharmaceutical Market.”